Chemotherapy for gynecologic cancers.

This review highlights significant recent developments and trends in chemotherapy for major gynecologic malignancies, i.e., ovarian cancer, endometrial cancer, uterine sarcomas, gestational trophoblastic neoplasia, and cervical cancer. In ovarian cancer, chemotherapeutic options for early, advanced and recurrent disease are in the adjuvant setting as well as in the neoadjuvant setting are explored. For uterine cancer, adjuvant chemotherapy is employed for high risk epithelial subtypes with early disease, such as uterine papillary serous carcinomas, uterine carcinosarcomas and leiomyosarcomas, advanced stage cases, as well as recurrent disease. The review then proceeds to further discuss the appropriate treatment based on the International Federation of Gynecology and Obstetrics prognostic scoring system for gestational trophoblastic neoplasia. Finally, chemotherapy is utilized in cervical cancer as neo-adjuvant therapy prior to surgery or radiation, as a sensitizer concomitantly with radiation therapy or for the treatment of advanced and recurrent disease.

[1]  L. Downs,et al.  A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. , 2011, Gynecologic oncology.

[2]  M. Hatae,et al.  Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  H. Sommer,et al.  Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Saif,et al.  Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review , 2010, Metal-based drugs.

[5]  S. Grunberg,et al.  Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study , 2010, Supportive Care in Cancer.

[6]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Iasonos,et al.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. , 2010, Gynecologic oncology.

[8]  M. Chamberlain Neurotoxicity of Cancer Treatment , 2010, Current oncology reports.

[9]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[10]  D. Cella,et al.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Sudhakar Tummala,et al.  NCCN task force report: management of neuropathy in cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[13]  Robert S Mannel,et al.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Voigt,et al.  Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. , 2009, European journal of cancer.

[15]  L. Asmar,et al.  Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Cella,et al.  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[17]  R. Berkowitz,et al.  Current management of gestational trophoblastic diseases. , 2009, Gynecologic oncology.

[18]  P. Sabbatini,et al.  Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. , 2009, Gynecologic oncology.

[19]  B. Monk,et al.  Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Grunberg,et al.  Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. , 2009, Clinical journal of oncology nursing.

[21]  G. Kenter,et al.  EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) , 2008 .

[22]  A. Sharifi,et al.  Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[23]  R. Mannel,et al.  A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. , 2008, Gynecologic oncology.

[24]  P. Schwartz What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? , 2008, Oncology.

[25]  N. Sebire,et al.  Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Deavers,et al.  Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. , 2008, Gynecologic oncology.

[27]  P. Hesketh Chemotherapy-induced nausea and vomiting. , 2008, The New England journal of medicine.

[28]  P. Rose,et al.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. , 2008, Gynecologic oncology.

[29]  A. Psyrri,et al.  Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. , 2008, Gynecologic oncology.

[30]  D. Katsaros,et al.  Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Roman,et al.  Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2007, American journal of clinical oncology.

[34]  H. Andersson,et al.  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long- term follow- up , 2007, International Journal of Gynecologic Cancer.

[35]  D. Mutch,et al.  Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Thigpen,et al.  Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Alberts,et al.  Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). , 2007, Gynecologic oncology.

[38]  J. Fine,et al.  Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. , 2007, Gynecologic oncology.

[39]  J. Desai,et al.  Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas , 2007, Cancer.

[40]  L. Einhorn,et al.  Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer , 2007, Supportive Care in Cancer.

[41]  C. Thomssen,et al.  Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. , 2007, Gynecologic oncology.

[42]  A. Berchuck,et al.  Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer , 2007, International Journal of Clinical Oncology.

[43]  A. Oza,et al.  Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer , 2007, Cancer.

[44]  T. Powles,et al.  A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia , 2007, British Journal of Cancer.

[45]  B. Monk,et al.  Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Esteban,et al.  Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas , 2007, Cancer Chemotherapy and Pharmacology.

[47]  S. Wilhelm,et al.  Prevention of Postoperative Nausea and Vomiting , 2007, The Annals of pharmacotherapy.

[48]  E. Eisenhauer,et al.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Jeffrey Bell,et al.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[50]  D. Bodurka,et al.  A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. , 2006, Gynecologic oncology.

[51]  P. Rose,et al.  Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2006, Gynecologic oncology.

[52]  J. Soper Gestational trophoblastic disease. , 2006, Obstetrics and gynecology.

[53]  A. Schott,et al.  What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. , 2006, Gynecologic oncology.

[54]  B. Dörken,et al.  Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. , 2006, Gynecologic oncology.

[55]  S. Waggoner,et al.  Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[56]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[57]  Joan L. Walker,et al.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  F. Lombardo,et al.  Extravasation of chemotherapeutic agents: prevention and treatment. , 2006, Seminars in oncology.

[59]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[60]  B. Monk,et al.  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. McAlpine,et al.  Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. , 2005, Gynecologic oncology.

[62]  D. Miller,et al.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  C. Aghajanian,et al.  Temozolomide in uterine leiomyosarcomas. , 2005, Gynecologic oncology.

[64]  A. Berger,et al.  Practical management of chemotherapy-induced nausea and vomiting. , 2005, Oncology.

[65]  G. Sutton,et al.  Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.

[66]  B. Monk,et al.  Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. , 2005, Gynecologic oncology.

[67]  G. Sutton,et al.  Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.

[68]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  G. Matsunaga,et al.  Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. , 2004, Gynecologic oncology.

[70]  D. Cella,et al.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Bentley,et al.  Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  M. Dimopoulos,et al.  Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer , 2004, Oncology.

[73]  E. Eisenhauer,et al.  The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group , 2004, International Journal of Gynecologic Cancer.

[74]  J. Lucci,et al.  Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. , 2004, Gynecologic oncology.

[75]  U. Matulonis,et al.  Phase II trial of anastrozole in women with asymptomatic müllerian cancer. , 2003, Gynecologic oncology.

[76]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Lea,et al.  Management of low-risk gestational trophoblastic neoplasia in indigent women. , 2003, The Journal of reproductive medicine.

[78]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  R. Broaddus,et al.  A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. , 2003, Gynecologic oncology.

[80]  M. Markman,et al.  Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. , 2003, Gynecologic oncology.

[81]  M. Morgan,et al.  Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Gary H Lyman,et al.  Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. , 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

[83]  G. Mor,et al.  Low-grade endometrial stromal sarcoma: hormonal aspects. , 2003, Gynecologic oncology.

[84]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[85]  N. Colombo,et al.  What have we learned from ICON1 and ACTION? , 2003, International Journal of Gynecologic Cancer.

[86]  M. Morgan,et al.  Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. , 2003, Gynecologic oncology.

[87]  Roger B. Lee,et al.  Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[88]  F. Amant,et al.  Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. , 2003, Gynecologic oncology.

[89]  M. Piccart,et al.  Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  P. Rose,et al.  A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[91]  D. Bodurka,et al.  Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  L. Pirtoli,et al.  Adjuvant Epirubicin With or Without Ifosfamide for Adult Soft-Tissue Sarcoma , 2002, American journal of clinical oncology.

[93]  H. Gabra,et al.  CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[94]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  J. Sorosky,et al.  Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  M. Johnston,et al.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. , 2002, Gynecologic oncology.

[97]  G. Rustin,et al.  Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  E. Kohorn Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance? , 2002, Gynecologic oncology.

[99]  C. Haie-meder,et al.  Results of conservative treatment in epithelial ovarian carcinoma , 2001, Cancer.

[100]  S. Wilailak,et al.  Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer , 2001, Anti-cancer drugs.

[101]  H. Hansen,et al.  Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. , 2001, Gynecologic oncology.

[102]  P. Zola,et al.  Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study. , 2001, European journal of cancer.

[103]  J. Kwon,et al.  Weekly intravenous methotrexate with folinic acid for nonmetastatic gestational trophoblastic neoplasia. , 2001, Gynecologic oncology.

[104]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  L. Muderspach,et al.  A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 2001, Gynecologic oncology.

[106]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  M. Brady,et al.  Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  E. Kohorn The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment , 2000, International Journal of Gynecologic Cancer.

[109]  G. Sutton,et al.  A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. , 2000, Gynecologic oncology.

[110]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Joan L. Walker,et al.  A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. , 2000, Gynecologic oncology.

[112]  J. Blay,et al.  Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  T. Herzog,et al.  Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. , 2000, Gynecologic oncology.

[114]  R. Talamini,et al.  Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  P. Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  C. Dunton,et al.  Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  R. Alvarez,et al.  Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[120]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[121]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[122]  B. Monk,et al.  Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. , 1999, Gynecologic oncology.

[123]  A. Benson,et al.  Recommended guidelines for the treatment of chemotherapy-induced diarrhea. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  F. Sopracordevole,et al.  Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. , 1998, Gynecologic oncology.

[125]  S. Kim,et al.  Effects of multiagent chemotherapy and independent risk factors in the treatment of high‐risk GTT —25 years experiences of KRI‐TRD , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[126]  E. Atkinson,et al.  Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  J A Blessing,et al.  Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  M. Piccart,et al.  Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. , 1997, European journal of cancer.

[129]  R. Winn,et al.  An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix , 1997, Anti-cancer drugs.

[130]  E S Newlands,et al.  EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  C. Verschraegen,et al.  Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  G. Sutton,et al.  Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study. , 1996, Gynecologic oncology.

[135]  S. Lentz,et al.  A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. , 1996, American journal of clinical oncology.

[136]  G. Sutton,et al.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[137]  D. Mutch,et al.  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[138]  K. Hatch,et al.  Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.

[139]  S. Nicosia,et al.  Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study. , 1996, Gynecologic oncology.

[140]  W. Mcguire,et al.  Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  M. Brady,et al.  High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[143]  O. Garrone,et al.  Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[145]  G. Sutton,et al.  A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Gynecologic oncology.

[146]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[147]  J. Kavanagh,et al.  Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. , 1993, Gynecologic oncology.

[148]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. , 1993, American journal of obstetrics and gynecology.

[149]  I. Vergote,et al.  Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. , 1992 .

[150]  Portal Hypertension: Clinical and Physiological Aspects , 1992, Annals of Internal Medicine.

[151]  M. Markman,et al.  Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  G. Sutton,et al.  Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study , 1992 .

[153]  S. Rubin,et al.  Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  R. Diasio,et al.  Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome , 1991, Cancer.

[155]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  D. Alberts,et al.  A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. , 1990, Gynecologic oncology.

[157]  S. Ellenberg,et al.  Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials , 1990, The New England journal of medicine.

[158]  R. O’Toole,et al.  Carboplatin therapy in advanced endometrial cancer , 1990, Obstetrics and gynecology.

[159]  J. Droz,et al.  Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. , 1990, The New England journal of medicine.

[160]  P. O'Brien,et al.  Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. , 1990, American journal of obstetrics and gynecology.

[161]  G. Sutton,et al.  Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix , 1989, Investigational New Drugs.

[162]  C. Redman,et al.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.

[163]  G. Marks,et al.  The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  F. Landoni,et al.  EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). , 1988, Gynecologic oncology.

[165]  M. Pasmantier,et al.  Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. , 1985, Cancer treatment reports.

[166]  S. Vogl,et al.  Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. , 1984, Gynecologic oncology.

[167]  R. Zaino,et al.  A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas , 1983, Cancer.

[168]  J. Herson,et al.  Cisplatin Chemotherapy for Disseminated Endometrial Cancer , 1982, Obstetrics and gynecology.

[169]  L. Lagasse,et al.  Cis‐platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: A phase ii study of the gynecologic oncology group , 1981, Cancer.

[170]  C. Cohen,et al.  Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. , 1980, Gynecologic oncology.

[171]  G. Ross,et al.  Primary chemotherapy for nonmetastatic gestational trophoblastic neoplasms. , 1967, American journal of obstetrics and gynecology.

[172]  W. Gradishar,et al.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  S. Groshen,et al.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  M. Parmar,et al.  Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[175]  G. Giaccone,et al.  Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[176]  J. Thigpen,et al.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  R. Schilder,et al.  Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2005, Gynecologic oncology.

[178]  P. Coyne,et al.  Symptom management , 2005, Bone Marrow Transplantation.

[179]  R. Souhami,et al.  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix , 2004, Cancer Chemotherapy and Pharmacology.

[180]  J. Fiorica,et al.  Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[181]  P. Disaia,et al.  Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. , 2003, Gynecologic oncology.

[182]  P. Rose,et al.  Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. , 2003, Gynecologic oncology.

[183]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[184]  D. Mutch,et al.  Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  V. D’addario,et al.  Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. , 1996, European journal of gynaecological oncology.

[186]  J. Vermorken,et al.  Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. , 1994, European journal of cancer.

[187]  Francesco Maneschi,et al.  Surgical pathological staging of endometrial carcinoma and results of treatment. , 1992, European journal of gynaecological oncology.

[188]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[189]  J. Thigpen,et al.  Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 1979, Cancer treatment reports.

[190]  U. Matulonis,et al.  Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases , 2022 .

[191]  P. Vasey,et al.  © 2001 Cancer Research Campaign , 2022 .